ASCO GU 2022 Kidney Cancer

Viewing 1-20 of 43 articles

ASCO GU 2022: Current Data on Predictive Biomarkers in Renal Cell Carcinoma

ASCO GU 2022: Germline Mutations of Interests in Renal Cell Carcinoma

ASCO GU 2022: Matching Sequencing Reports With Available Therapies in Renal Cell Carcinoma

ASCO GU 2022: Adjuvant and Consolidative Therapy in Oligometastatic Renal Cell Carcinoma

ASCO GU 2022: Updates on Clinical Trials in First-Line Metastatic Renal Cell Carcinoma Plus Novel Pathways and Endpoints

ASCO GU 2022: Updates on Clinical Trials in Adjuvant Renal Cell Carcinoma

ASCO GU 2022: SWOG S1931 (PROBE): Phase III Randomized Trial of Immune Checkpoint Inhibitor Combination Regimen with or Without Cytoreductive Nephrectomy in Advanced Renal Cancer

ASCO GU 2022: Prolonging Utilization of Systemic Therapy in Oligoprogressive Metastatic Renal Cell Carcinoma Using Stereotactic Body Radiation Therapy

ASCO GU 2022: Association of Adrenal Metastases With Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma Treated With Nivolumab in the GETUG-AFU-26 NIVOREN Phase II Trial

ASCO GU 2022: Efficacy and Safety of Lenvatinib Plus Pembrolizumab Versus Sunitinibin the East Asian Subset of Patients With Advanced Renal Cell Carcinoma From the Phase 3 CLEAR Trial

ASCO GU 2022: Tivozanib As First-Line Treatment of Metastatic Renal Cell Carcinoma: A Real-World Outcome Review in North-West of England, UK

ASCO GU 2022: Characterizing IMDC Prognostic Groups in Contemporary First-Line Combination Therapies for mRCC

ASCO GU 2022: CABOSEQ: The Efficacy of Cabozantinib Post Up-Front Immuno-Oncology Combinations in Patients with Advanced Renal Cell Carcinoma: Results from the IMDC

ASCO GU 2022: Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in mRCC: Results From the Canadian Kidney Cancer Information System

ASCO GU 2022: HRQoL in Previously Untreated Patients With Advanced Renal Cell Carcinoma: CheckMate 9ER Updated Results

ASCO GU 2022: Pathologic Outcomes at Cytoreductive Nephrectomy Following Immunotherapy for Patients With Advanced RCC

ASCO GU 2022: First-Line Therapy for Metastatic Renal Cell Carcinoma With Pancreatic Metastases: Results From the IMDC

ASCO GU 2022: Safety and Differential Clinical Activity of Nivolumab plus Ipilimumab in Patients with Non-Clear Cell RCC

ASCO GU 2022: Predictors of Objective Response to First-Line Immuno-Oncology Combination Therapies in Metastatic Renal Cell Carcinoma: Results from the IMDC

ASCO GU 2022: Phase II Study of Nivolumab and Salvage Nivolumab + Ipilimumab in Treatment-Naïve Patients with Advanced Clear Cell Renal Cell (HCRN GU16-260-Cohort A): Final Report

1
2
3

email news signup